Category: pharmacological
Aliases: NS-2330
Triple monoamine reuptake inhibitor (DAT + NET + SERT). Originally trialed for Alzheimer + Parkinson, abandoned, then resurrected for obesity — Phase 2 weight loss ~10% at 6 months. Approved in Mexico / Argentina for obesity; not FDA-approved.
PO: 220h